The new guidelines call for better access to CDK4/6 inhibitors and anti-HER2 therapies for patients with advanced breast cancer. Experts also stress the need for adequate pain control, particularly in countries where opioids are scarce or misused.
The study found that T-DM1 resulted in a third of patients experiencing objective response and nearly 40% continuing treatment for at least six months. Patients with central nervous system metastases had shorter progression-free survival rates, highlighting the need for inclusion in randomized trials.
Complementary therapies used to treat breast cancer skin lesions may delay wound healing and interfere with systemic treatments. Herbal products like green chiretta and feverfew have been shown to negatively impact blood clotting, exacerbating scarring and dressing effectiveness.
Advanced breast cancer patients frequently receive inaccurate one-number estimates of their average survival time. Instead, a new method provides doctors with three scenarios: best-case, worst-case and typical survival times. This approach has been shown to be more helpful, easier to understand and reassuring for patients.
Professor Fatima Cardoso will receive the award for her foresight in understanding advanced breast cancer and launching the ABC Global Alliance. The alliance, now an independent organization, aims to improve lives of patients worldwide through awareness and advocacy.
Experts say pre-menopausal women with hormone-dependent advanced breast cancer should be included in clinical trials alongside older women. This could provide valuable insights into the best treatments for these patients, who make up a third of all advanced breast cancer cases globally.
Regular exercise can reduce fatigue and pain, and improve cardiovascular health and quality of life in women with advanced breast cancer. The study found that women who exercised had a 12.3% increase in VO2max compared to the control group, indicating improved oxygen transportation and heart function.
Researchers found that combining targeted drugs with hormone therapy results in a significant increase in the risk of severe or life-threatening adverse events. Most of these side effects are treatable and potentially preventable.
Patients with advanced breast cancer who experience delayed disease progression have better quality of life outcomes compared to those whose disease progresses earlier. Delaying progression could be critical in improving health-related quality of life for patients with oestrogen receptor positive, HER2 negative advanced breast cancer.
The ABC Global Alliance, led by ESO, has launched a call-to-action to improve and extend the lives of patients with advanced breast cancer by 2025. The initiative outlines key gaps and actionable imperatives across patient care, societal support, and scientific investment for mBC.
A new clinical trial is proposed to investigate the best ways for identifying and treating advanced breast cancer patients who can survive for long periods without their disease progressing. The guidelines emphasize the importance of harnessing technology to improve cancer treatment, particularly for patients in remote areas.
Experts discuss the impact of affordable medicines on breast cancer treatment, highlighting the importance of healthcare structures in improving patient outcomes. The lack of effective systems can negate even new, expensive treatments.
Researchers found that insulin resistance is associated with a significantly worse prognosis for metastatic breast cancer patients. Lifestyle changes, such as diet and exercise, may help improve outcomes. Insulin targeting therapies could also be beneficial.
Patient advocates urge medical professionals and policymakers to consider the long-term effects of advanced breast cancer treatments. They highlight the need for accessible therapies that extend patients' lives, while also addressing financial, employment, and family challenges associated with prolonged illness. Experts note that curre...
Cancer experts will discuss how to work together to accelerate progress towards a cure, expand global access to prevention, treatment, and care. The World Economic Forum is the right platform to address the urgent need for bold action.
A retrospective study published in The Lancet found no excess risk of cancer among individuals who received blood products from donors with previously diagnosed cancers. The study included over 12,000 exposed individuals and 342,082 unexposed individuals, concluding that long-term cancer survivors might be a safe donor group.
A recent study found that nodal status is the strongest determinant of outcome after neoadjuvant therapy for esophageal cancer. Patients with complete pathological responses had better survival rates, but only if they also had no nodal involvement.
Pawel Walewski, a health editor with Poland's biggest selling weekly magazine Polityka, has been awarded the European School of Oncology's Best Cancer Reporter Award for 2007. The award recognizes his outstanding cancer reporting and aims to promote better quality media coverage of cancer.
Patients treated at high volume centers have better 30-day and 5-year survival rates compared to those at low volume centers. High-grade tumors and larger tumor sizes are less common in high volume centers, yet outcomes remain superior.